These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1144 related items for PubMed ID: 22985747

  • 1. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE, Jung IT, Choi J, Baek YH, Lee JD, Park DS, Choi DY.
    Eur J Pharmacol; 2013 Jan 05; 698(1-3):57-66. PubMed ID: 22985747
    [Abstract] [Full Text] [Related]

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J.
    J Bone Miner Res; 2012 Jun 05; 27(6):1298-1308. PubMed ID: 22337253
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.
    J Bone Miner Res; 2003 Dec 05; 18(12):2159-68. PubMed ID: 14672351
    [Abstract] [Full Text] [Related]

  • 6. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki M, Tang CH.
    Eur J Pharmacol; 2008 Jun 24; 588(1):124-33. PubMed ID: 18495114
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
    J Bone Miner Res; 2005 Apr 24; 20(4):653-62. PubMed ID: 15765185
    [Abstract] [Full Text] [Related]

  • 8. The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation.
    Tang CH, Chang CS, Tan TW, Liu SC, Liu JF.
    Eur J Pharmacol; 2010 Dec 01; 648(1-3):59-66. PubMed ID: 20850430
    [Abstract] [Full Text] [Related]

  • 9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar 15; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
    Konda VR, Desai A, Darland G, Bland JS, Tripp ML.
    Arthritis Rheum; 2010 Jun 15; 62(6):1683-92. PubMed ID: 20201075
    [Abstract] [Full Text] [Related]

  • 13. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, Yoneda T.
    J Bone Miner Res; 2008 Jun 15; 23(6):907-14. PubMed ID: 18251700
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation.
    Hirayama T, Dai S, Abbas S, Yamanaka Y, Abu-Amer Y.
    Arthritis Rheum; 2005 Sep 15; 52(9):2719-29. PubMed ID: 16142755
    [Abstract] [Full Text] [Related]

  • 15. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L, Lee J, Jang JH, Lee SH, Nan MH, Oh BC, Lee SG, Kim HH, Soung NK, Ahn JS, Kim BY.
    Bone; 2012 Jun 15; 50(6):1207-13. PubMed ID: 22484180
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L, Wei H, Wu Y, Yang S, Xiao L, Zhang J, Peng B.
    Int J Biochem Cell Biol; 2012 Jul 15; 44(7):1139-52. PubMed ID: 22521613
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.
    Bone; 2015 Oct 15; 79():242-51. PubMed ID: 26103094
    [Abstract] [Full Text] [Related]

  • 20. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
    Kim WS, Kim HJ, Lee ZH, Lee Y, Kim HH.
    Exp Cell Res; 2013 Feb 15; 319(4):436-46. PubMed ID: 23246654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.